A1 Refereed original research article in a scientific journal
Longitudinal and cross-sectional associations of myocardial stress markers with kidney function and chronic kidney disease in the BiomarCaRE project
Authors: Lin, Jie-Sheng; Zeller, Tanja; Koenig, Wolfgang; Jousilahti, Pekka; Kee, Frank; Iacoviello, Licia; Tunstall-Pedoe, Hugh; Söderberg, Stefan; Cesana, Giancarlo; Palmieri, Luigi; Salomaa, Veikko; de Man Lapidoth, Julia; De Ponti, Roberto; Donfrancesco, Chiara; Lorenz, Thiess; Kuulasmaa, Kari; Blankenberg, Stefan; Peters, Annette; Thorand Barbara
Publisher: Springer Nature
Publication year: 2026
Journal: Scientific Reports
Article number: 7488
Volume: 16
eISSN: 2045-2322
DOI: https://doi.org/10.1038/s41598-026-37377-2
Publication's open availability at the time of reporting: Open Access
Publication channel's open availability : Open Access publication channel
Web address : https://doi.org/10.1038/s41598-026-37377-2
Self-archived copy’s web address: https://research.utu.fi/converis/portal/detail/Publication/515720184
Self-archived copy's licence: CC BY
Self-archived copy's version: Publisher`s PDF
Given the complex relationship between cardiovascular disease (CVD) and chronic kidney disease (CKD), CVD-related markers may serve as CKD biomarkers. We examined associations of three major CVD-markers [mid-regional pro-adrenomedullin (MR-proADM), MR-pro-atrial natriuretic peptide (MR-proANP), and N-terminal pro-B-type natriuretic peptide (NT-proBNP)] with CKD. Cross-sectional analyses included up to 61,830 participants, and longitudinal analyses (NT-proBNP only) 4205 individuals. Kidney function was assessed by estimated glomerular filtration rate (eGFR) using creatinine, cystatin C, or both (eGFRcr-cys). Markers were categorized into four groups. Cross-sectional analyses found that higher levels of all three markers were consistently associated with lower eGFR and higher CKD prevalence. For example, per 1 standard deviation (SD) increase in log-transformed NT-proBNP, corresponding to a 2.71-fold increase in the original concentration, was associated with -2.35 (-2.49, -2.21) ml/min/1.73m2 lower eGFRcr-cys, and the highest NT-proBNP group had a 5.72-fold higher odds of CKDcr-cys (eGFRcr-cys < 60 ml/min/1.73m2) compared with the lowest. Associations with eGFR were stronger among participants with CVD and diabetes. In longitudinal analyses, participants with higher baseline NT-proBNP had faster declines in eGFR, with a 10-year decline of -1.37 (-1.77, -0.98) ml/min/1.73m2 eGFRcr-cys per 1 SD increase, and higher CKD incidence. These findings suggest MR-proADM, MR-proANP, and NT-proBNP as CKD biomarkers.
Downloadable publication This is an electronic reprint of the original article. |  |
Funding information in the publication:
Open Access funding enabled and organized by Projekt DEAL. The MORGAM Project has received funding from EU projects MORGAM (Biomed, BMH4-CT98-3183), GenomEUtwin (FP5, QLG2-CT-2002–01254), ENGAGE (FP7, HEALTH-F4-2007–201413), CHANCES (FP7, HEALTH-F3-2010–242244), BiomarCaRE (FP7, HEALTH-F2-2011–278913), euCanSHare (Horizon 2020, No. 825903) and AFFECT-EU (Horizon 2020, No. 847770); and Medical Research Council, London (G0601463, No. 80983: Biomarkers in the MORGAM Populations). This has supported central coordination, workshops and part of the activities of the MORGAM Data Centre, the MORGAM Laboratories and the MORGAM Participating Centres. The MONICA/KORA study was initiated and financed by the Helmholtz Zentrum München – German Research Center for Environmental Health, which is funded by the German Federal Ministry of Education and Research (BMBF) and by the State of Bavaria. Data collection in the MONICA/KORA study is done in cooperation with the University Hospital of Augsburg. Northern Sweden MONICA was funded by the county councils in Norr- and Västerbotten, Umeå University, Swedish Research Council and Swedish Heart and Lung Foundation. The funders had no role in study design, data collection, analysis, decision to publish, or preparation of the manuscript.
